Free Trial

Avanos Medical (AVNS) Competitors

Avanos Medical logo
$12.35 -0.03 (-0.24%)
As of 07/3/2025 03:30 PM Eastern

AVNS vs. NVCR, LMAT, EYE, ENOV, CNMD, TNDM, SSII, CDRE, AORT, and LQDA

Should you be buying Avanos Medical stock or one of its competitors? The main competitors of Avanos Medical include NovoCure (NVCR), LeMaitre Vascular (LMAT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), Tandem Diabetes Care (TNDM), SS Innovations International (SSII), Cadre (CDRE), Artivion (AORT), and Liquidia Technologies (LQDA). These companies are all part of the "medical equipment" industry.

Avanos Medical vs. Its Competitors

NovoCure (NASDAQ:NVCR) and Avanos Medical (NYSE:AVNS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

In the previous week, NovoCure had 6 more articles in the media than Avanos Medical. MarketBeat recorded 6 mentions for NovoCure and 0 mentions for Avanos Medical. NovoCure's average media sentiment score of 0.39 beat Avanos Medical's score of 0.00 indicating that NovoCure is being referred to more favorably in the media.

Company Overall Sentiment
NovoCure Neutral
Avanos Medical Neutral

NovoCure has higher earnings, but lower revenue than Avanos Medical. NovoCure is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoCure$605.22M3.26-$168.63M-$1.51-11.73
Avanos Medical$687.80M0.83-$392.10M-$8.37-1.48

NovoCure has a net margin of -26.41% compared to Avanos Medical's net margin of -55.80%. Avanos Medical's return on equity of 6.26% beat NovoCure's return on equity.

Company Net Margins Return on Equity Return on Assets
NovoCure-26.41% -45.46% -13.34%
Avanos Medical -55.80%6.26%4.63%

NovoCure currently has a consensus price target of $32.83, indicating a potential upside of 85.45%. Given NovoCure's stronger consensus rating and higher probable upside, equities analysts plainly believe NovoCure is more favorable than Avanos Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NovoCure
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67
Avanos Medical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

NovoCure has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, Avanos Medical has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.

84.6% of NovoCure shares are owned by institutional investors. Comparatively, 95.2% of Avanos Medical shares are owned by institutional investors. 5.5% of NovoCure shares are owned by company insiders. Comparatively, 2.6% of Avanos Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

NovoCure beats Avanos Medical on 10 of the 16 factors compared between the two stocks.

Get Avanos Medical News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVNS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVNS vs. The Competition

MetricAvanos MedicalMED INSTRUMENTS IndustryMedical SectorNYSE Exchange
Market Cap$571.11M$6.86B$5.54B$20.72B
Dividend YieldN/A1.21%5.24%3.72%
P/E Ratio-1.4826.1527.4328.09
Price / Sales0.8399.70420.7938.30
Price / Cash1.0421.0936.8922.53
Price / Book0.684.748.044.58
Net Income-$392.10M$173.18M$3.18B$986.06M
7 Day Performance1.19%1.33%2.88%2.79%
1 Month Performance0.10%0.16%3.69%5.46%
1 Year Performance-36.08%23.71%36.15%15.06%

Avanos Medical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVNS
Avanos Medical
N/A$12.35
-0.2%
N/A-36.4%$571.11M$687.80M-1.482,227
NVCR
NovoCure
3.6878 of 5 stars
$16.61
-0.5%
$32.83
+97.7%
+4.9%$1.86B$605.22M-11.001,488
LMAT
LeMaitre Vascular
2.7173 of 5 stars
$83.38
+2.0%
$97.83
+17.3%
+3.8%$1.85B$219.86M42.11490Positive News
EYE
National Vision
2.6546 of 5 stars
$22.69
-0.8%
$18.67
-17.7%
+92.2%$1.81B$1.82B-68.7613,411Positive News
ENOV
Enovis
3.549 of 5 stars
$30.01
-0.3%
$58.00
+93.3%
-24.3%$1.72B$2.11B-2.157,367Positive News
CNMD
CONMED
4.6558 of 5 stars
$51.72
-0.9%
$62.20
+20.3%
-19.5%$1.61B$1.31B13.613,900
TNDM
Tandem Diabetes Care
4.2181 of 5 stars
$20.22
flat
$33.43
+65.3%
-57.1%$1.35B$940.20M-7.272,650Positive News
SSII
SS Innovations International
N/A$5.65
-18.4%
N/AN/A$1.34B$22.13M0.004Gap Down
CDRE
Cadre
3.6847 of 5 stars
$32.76
-0.3%
$37.50
+14.5%
-5.3%$1.34B$567.56M34.482,284
AORT
Artivion
2.4992 of 5 stars
$30.84
+1.9%
$32.00
+3.8%
+18.8%$1.29B$388.54M-61.671,600
LQDA
Liquidia Technologies
3.2403 of 5 stars
$13.26
+0.7%
$26.89
+102.8%
+2.4%$1.13B$14M-8.3950Positive News

Related Companies and Tools


This page (NYSE:AVNS) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners